×

Biotech and Pharmaceuticals Medicine

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. "These are highly encouraging...

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a major boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. The drug, which will have the...

  • Merck CEO: We're doing the right studies to make KeyTruda broadly available

    Merck CEO Kenneth Frazier speaks to CNBC's Meg Tirrell about the FDA's approval of the company's lung cancer treatment KeyTruda and the general fight against cancer.

  • *Danish group looking for new drugs "adjacent" to diabetes. LONDON, May 11- Hit by pricing pressure in its core insulin business, Danish drugmaker Novo Nordisk is looking at new treatments for obesity- a major cause of diabetes- to help revive its growth. By contrast, Novo's newly approved anti-obesity injection Saxenda, launched in 2015 and containing the same GLP-1...

  • NEW YORK, May 10- U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront. Shares of Sangamo jumped 41 percent to $6.15 in after-the-bell trading. Michael Goettler, global...

  • Pharmacist Pharmacy medication

    The high cost of health care in the US is nothing compared to the markup on some prescription medicines. We reveal the most expensive drugs.

  • *Analysts say failure puts approval at risk. ZURICH, May 10- Roche's Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine. Roche, the world's biggest maker of cancer drugs, had won...

  • ZURICH, May 10- Roche's Tecentriq drug has failed a late-stage trial in people with previously treated advanced bladder cancer, the Swiss drugmaker said on Wednesday, a setback in its plans to expand use of the immunotherapy. "While these results are not what we had expected, we believe that Tecentriq will continue to play an important role in the treatment of...

  • May 9- U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno-oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA. In March, Bavencio was approved by the Food and Drug Administration to treat a rare skin cancer...

  • The U.S. healthcare company said its Janssen Biotech Inc unit received a civil investigative demand from the Justice Department regarding an investigation under the False Claims Act related to its arthritis drugs Remicade and Simponi Aria. J&J also revealed in its quarterly filing that the U.S. Attorney's Office in Massachusetts is seeking documents...

  • May 8- Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States. The abuse of opioids a class of drugs that include heroin and prescription painkillers has assumed epidemic proportions in the United...

  • May 8- Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States. The abuse of opioids a class of drugs that include heroin and prescription painkillers has assumed epidemic proportions in the United...

  • Dr. Kenneth Davis

    Those who lose coverage and are sick still need treatment; where will that money come from? Mt. Sinai CEO Dr. Kenneth Davis asked.

  • A woman who said she had a pre-existing condition that made it impossible to find insurance that would cover her until the Affordable Care Act, is examined by a doctor during a routine checkup at a community health clinic in Miami, Florida.

    The answer on how to deal with people with pre-existing conditions is to create an insurance market just for them, John Goodman told CNBC.

  • Rep. Markwayne Mullin

    People with pre-existing conditions will "absolutely" be covered at an affordable price under the GOP health-care bill, Rep. Mullin said.

  • Half a million people die every year from preventable disease: Kaiser Permanente CEO

    Robert Pearl, The Permanente Medical Group CEO, weighs in on his book and the health-care bill hitting the floor today.

  • Alzheimer’s has lagged other health issues when it comes to advocacy. That’s changing, as Alzheimer’s groups push the funding fight.

  • Medicine Man dispensary

    Spending on prescription medicines in the U.S. will increase 4 percent to 7 percent through 2021, reaching $580 billion to $610 billion.

  • BEVERLY HILLS, Calif., May 3- After years of discord with a prominent hedge-fund manager, a federal investigation and bad publicity, Herbalife Ltd Chief Executive Officer Michael Johnson is taking a victory lap. At the Milken Institute Global Conference this week, Johnson touted the wares of his nutritional supplement maker, offering free shakes and protein...

  • Bayer's Head of Innovation, Kemal Malik, explains how the revolutionary gene editing technique it invested in will not just treat but cure serious diseases.